ArticleOpen forum infectious diseases2025
Risk Factors and Outcome of HHV-6 Infections After Allogeneic Hematopoietic Cell Transplantation.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committee.Bone marrow transplantation · 2026Guideline
- Rapid HHV-6 Clearance Following Preemptive Short-Course Foscarnet in Allogeneic Stem Cell Transplant Recipients.American journal of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human herpesvirus 6 (HHV-6) reactivation is frequently seen in recipients of allogeneic hematopoietic cell (HCT) transplantation, but data on clinical outcomes and risk factors are scarce. We aimed to assess the epidemiological features and outcome of clinically relevant HHV-6 infections in the first 180 days after transplantation. Methods: This was a single-center retrospective study of 405 consecutive allogeneic HCT recipients. We matched cases with a clinically relevant HHV-6 infection with control patients. Results: We found an cumulative incidence of 3.7% (95% confidence interval [CI], 1.9-5.5) and an overall incidence rate of 8.84 per 100 person-years (95% CI, 4.95-14.6) of clinically relevant HHV-6 infections during the study period. Adjusting for HCT-specific comorbidity index category, conditioning regimen, donor type, and acute graft-versus-host disease severity, the occurrence of HHV-6 encephalitis was significantly associated with a higher hazard of nonrelapse mortality (hazard ratio, 3.821; 95% CI, 1.437-10.155; Conclusions: HHV-6 encephalitis remains the most detrimental disease manifestation and posttransplant factors related to immune suppression are to be included in future epidemiological studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.